Health news
The Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of moderate to severe atopic dermatitis in pediatric patients aged 6 months to 5 years whose disease is not adequately controlled with…
Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in skin clearance at 1 year of treatment, according to long-term findings from two phase 3 trials. Lebrikizumab is a novel humanized monoclonal…
A potential protective effect of allergic diseases on serum lipid levels was identified in results from a study published in Frontiers in Medicine. In a biobank-based study of adult patients in the UK, both asthma…
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab as an add-on maintenance treatment for moderate to severe atopic dermatitis in pediatric patients aged 6…
Lilly has decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus. The decision was made based on data from 2 pivotal phase 3 trials, SLE-BRAVE-I (ClinicalTrials.gov Identifier:…
Projected demographic shifts in the US underscore the need for knowledgeable dermatologists who are competent in caring for patients with skin of color (SoC). Individuals with Fitzpatrick’s skin phototypes 4 through 6 may represent more…
The Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of refractory, moderate to severe atopic dermatitis in patients 12 years of age and older whose disease is not adequately controlled with…
Atopic dermatitis is associated with shorter stature, increased body mass index (BMI), and lower weight in early childhood, although the associations with height and BMI are attenuated as the children age, according to study data…
Treatment with lebrikizumab plus topical corticosteroids (TCS) was associated with significant skin improvement in patients with moderate to severe atopic dermatitis, according to data from the phase 3 ADhere trial. Lebrikizumab is a novel humanized…
Hair loss is separated into two categories. Cicatricial alopecia, characterized by inflammation that permanently damages the hair follicle, is uncommon. In clinical practice, noncicatricial types make up the majority of cases of alopecia. Whereas male…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021